Malaria death rates reduce by 60% since 2000, shows WHO-UNICEF report

Malaria death rates have plunged by 60 per cent since 2000, translating into 6.2 million lives saved, the vast majority of them children, according to a joint WHO-UNICEF report released today.

The report – Achieving the Malaria Millennium Development Goal Targetshows that the malaria MDG target to “have halted and begun to reverse the incidence” of malaria by 2015, has been met “convincingly”, with new malaria cases dropping by 37 per cent in 15 years.

“Global malaria control is one of the great public health success stories of the past 15 years,” said Dr. Margaret Chan, Director-General of WHO. “It’s a sign that our strategies are on target, and that we can beat this ancient killer, which still claims hundreds of thousands of lives, mostly children, each year.”

An increasing number of countries are on the verge of eliminating malaria. In 2014, 13 countries reported zero cases of the disease and 6 countries reported fewer than 10 cases. The fastest decreases were seen in the Caucasus and Central Asia, which reported zero cases in 2014, and in Eastern Asia.

Journey not over

Despite tremendous progress, malaria remains an acute public health problem in many regions. In 2015 alone, there were an estimated 214 million new cases of malaria, and approximately 438,000 people died of this preventable and treatable disease. About 3.2 billion people – almost half of the world’s population – are at risk of malaria.

Some countries continue to carry a disproportionately high share of the global malaria burden. Fifteen countries, mainly in sub-Saharan Africa, accounted for 80 per cent of malaria cases and 78 per cent of deaths globally in 2015.

Children under 5 account for more than two-thirds of all deaths associated with malaria. Between 2000 and 2015, the under-5 malaria death rate fell by 65 per cent or an estimated 5.9 million child lives saved.

“Malaria kills mostly young children, especially those living in the poorest and most remote places. So the best way to celebrate global progress in the fight against it is to recommit ourselves to reaching and treating them,” said UNICEF Executive Director Anthony Lake. “We know how to prevent and treat malaria. Since we can do it, we must.”

A surge in funding – but not enough

Global bi-lateral and multi-lateral funding for malaria has increased 20-fold since 2000. Domestic investments within malaria-affected countries have also increased year by year.

A number of donor governments have made the fight against malaria a high global health priority. In the United States of America, the President’s Malaria Initiative has mobilized hundreds of millions of dollars for treatment and prevention, while the government of the United Kingdomtripled its funding for malaria control between 2008 and 2015.

Many governments have also channeled their investments through the Global Fund to Fight AIDS, Tuberculosis and Malaria or directly to countries.

“A healthy, prosperous world is in all our interests and the prevention of deadly diseases is one of the smartest investments we can make.” said the Rt. Hon. Justine Greening, Secretary of State for International Development of the United Kingdom. “That is why, working with malaria-affected countries and partners like the Global Fund, Britain will continue to provide bednets to millions, tackle resistance to life saving medicines and insecticides, and boost health systems across Africa to help bring an end to this terrible disease.”

The surge in funding has led to an unprecedented expansion in the delivery of core interventions across sub-Saharan Africa. Since 2000, approximately 1 billion insecticide-treated bednets (ITNs) have been distributed in Africa. The increased use of rapid diagnostic tests (RDTs) has made it easier to distinguish between malarial and non-malarial fevers, enabling timely and appropriate treatment. Artemisinin-based combination therapies (ACTs) are highly effective against Plasmodium falciparum, the most prevalent and lethal malaria parasite affecting humans, but drug resistance is a looming threat which must be prevented.

New research demonstrates the impact of core interventions

New research from the Malaria Atlas Project – a WHO Collaborating Centre based at the University of Oxford – shows that ITNs have been by“far the most important intervention” across Africa, accounting for an estimated 68 per cent of malaria cases prevented since 2000. ACTs and indoor residual spraying contributed to 22 per cent and 10 per cent of cases prevented, respectively. The research, published yesterday in the journal Nature, provides strong support for increasing access to these core interventions in post-2015 malaria control strategies.

The way forward

In May 2015, the World Health Assembly adopted the WHO Global Technical Strategy for Malaria—a new 15-year road map for malaria control. The strategy aims at a further 90 per cent reduction in global malaria incidence and mortality by 2030.

The WHO-UNICEF report notes that these targets can only be achieved with political will, country leadership and significantly increased investment. Annual funding for malaria will need to triple—from $2.7 billion today to $8.7 billion in 2030.

Other key findings from the report:

In 2015, 89 per cent of all malaria cases and 91 per cent of deaths were in sub-Saharan Africa.

  • Of the 106 countries and territories with malaria transmission in 2000, 102 are projected to reverse the incidence of malaria by the end of 2015.
  • Between 2000 and 2015, the proportion of children under five sleeping under an ITN in sub-Saharan Africa increased from less than 2 per cent to an estimated 68 per cent.
  • 1 in 4 children in sub-Saharan Africa still lives in a household with no ITN and no protection provided by indoor residual spraying.

In 2015, only an estimated 13 per cent of children with a fever in sub-Saharan Africa received an ACT.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Artemisinin resistance detected in children with severe malaria in Uganda